Adaptimmune Q2 2021 Earnings Report
Key Takeaways
Adaptimmune reported financial results for the second quarter ended June 30, 2021. The company had cash and cash equivalents of $50.5 million and Total Liquidity of $285.4 million. Revenue for the quarter was $3.1 million, and the company believes its existing funds will support operations into early 2023.
SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year.
SURPASS trial data from 23 evaluable patients to be presented at ESMO.
ADP-A2AFP Phase 1 trial data from 11 evaluable patients in Group 3/Expansion to be presented at ILCA.
Financial guidance confirmed: funded into early 2023.
Adaptimmune
Adaptimmune
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into early 2023.